I like the thinking outside the box.
the risks regarding a competitor(is new drug or mechanism) is much less so. As a drug that is made from scratch or just discovered to do something still has to go through the whole drug process, unless they find a drug like bisantrene that has already been through trials in the past. Certainly possible, highly improbable but I guess a risk all the same.
over expressed cancer becoming resistant would be an issue for the acquirer of the drug I would assume, as I assume that would be something over time.
being poached is possible, but if all board sees things the same as Dr T, I would think they would see so much upside it would be av step down financially. Obviously taking into consideration the risk.
unfortunately, I can't argue whether Dr T is delusional or not... I'll just leave that as a risk
MST valuation of RAC, page-174
-
- There are more pages in this discussion • 123 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
-0.015(0.95%) |
Mkt cap ! $265.8M | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.63 | $1.56 | $160.1K | 100.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 222 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |